📰 Nasdaq Alt News
Nasdaq Alt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Alt. Real-time updates on events, politics, business and more.
May 3, 2024
Guggenheim downgraded shares of Altimmune (NASDAQ:ALT – Free Report) from a buy rating to a neutral rating in a research note released on Monday, Marketbeat reports. Several other analysts have also commented on the stock. B. Riley reaffirmed a buy rating and issued a $20.00 price objective on shares of Altimmune in a research report […]
April 22, 2024
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) shot up 6.5% during trading on Monday . The stock traded as high as $7.37 and last traded at $7.36. 1,032,095 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 5,444,214 shares. The stock had previously closed at $6.91. Analyst Upgrades […]
April 4, 2024
Altimmune (NASDAQ:ALT – Free Report) had its price target reduced by HC Wainwright from $15.00 to $12.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the stock. ALT has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on shares […]
March 28, 2024
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) traded up 5.3% on Thursday . The company traded as high as $9.38 and last traded at $9.36. 660,352 shares changed hands during trading, a decline of 89% from the average session volume of 5,935,036 shares. The stock had previously closed at $8.89. Analyst Ratings Changes A number […]
March 25, 2024
Connective Portfolio Management LLC acquired a new stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) in the fourth quarter, Holdings Channel reports. The firm acquired 16,000 shares of the company’s stock, valued at approximately $180,000. Several other hedge funds have also recently modified their holdings of ALT. FNY Investment Advisers LLC purchased a […]
March 25, 2024
Connective Portfolio Management LLC bought a new stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,000 shares of the company’s stock, valued at approximately $180,000. Other hedge funds and other institutional investors also recently […]
March 10, 2024
GSA Capital Partners LLP raised its stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 153.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 445,868 shares of the company’s stock after purchasing an additional 269,676 shares during the quarter. GSA Capital […]
February 14, 2024
B. Riley reissued their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $20.00 target price on the stock. A number of other brokerages have also weighed in on ALT. The Goldman Sachs Group started coverage on shares of Altimmune […]
February 13, 2024
WealthPlan Investment Management LLC purchased a new position in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,931 shares of the company’s stock, valued at approximately $31,000. A number of other institutional investors and hedge funds also […]
February 8, 2024
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) was up 5.8% during trading on Tuesday . The company traded as high as $10.06 and last traded at $9.93. Approximately 926,426 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 6,349,605 shares. The stock had previously closed at $9.39. Wall […]